Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
T

Trastuzumab

Availability of ACE Drug Guidance

No

Biologics Drug Information Overview

Yes

Post-marketing information

Dear Healthcare Professional Letters

Subsidy Information and Financing Scheme

Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List

Standard Drug List

Active ingredient: Trastuzumab

General information

Subsidy Information and Financing Scheme

[SDL] Trastuzumab Biosimilar (Herzuma) Injection 440 mg

[SDL] Trastuzumab Biosimilar (Ogivri) Injection 440 mg

[MSHL] Trastuzumab Powder For IV Infusion 440 mg

  1. For cancer treatment in line with HSA registered indication(s).

  2. Pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.

  3. Pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year.

  4. Pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.

  5. For the treatment of locally advanced unresectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting.

[MSHL] Trastuzumab Solution For SC Injection 600 mg/5 mL

  1. For cancer treatment in line with HSA registered indication(s).

  2. Pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.

  3. Pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year.

  4. Pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.

  5. For the treatment of locally advanced unresectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting.

[MSHL] Trastuzumab biosimilar Powder For IV Infusion 440 mg

  1. For cancer treatment.

  2. Pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.

  3. Pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year.

  4. Pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.

  5. For the treatment of locally advanced unresectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting.

[MSHL] Trastuzumab biosimilar Powder For Concentrate For Solution For Infusion 150 mg, 420 mg

  1. For cancer treatment.

View legend

Drug Guidance for Subsidy

Not Applicable

Post Marketing Information

DHCPL 26/06/2020 Herceptin (trastuzumab): Herceptin Solvent Vials/20ml co-packaged with Herceptin Powder for Injection 440 mg (SIN11028P) – Voluntary recall of batches N3928B04, N3930B03, N3931B03 and N3931B07

DHCPL 24/01/2014 Potential risk for medication error between Kadcyla® (trastuzumab emtansine) and Herceptin® (trastuzumab) resulting from name confusion

DHCPL 06/03/2013 TYKERB© (lapatinib ditosylate monohydrate) – Comparative data have shown that Lapatinib based regimens are less effective than Herceptin© (trastuzumab) based regimens in certain settings

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Herzuma Injection 440 mg

  1. KK Women's and Children's Hospital

  2. National Cancer Centre

  3. National University Hospital

  4. Singapore General Hospital

  5. Tan Tock Seng Hospital

Ogivri Injection 440 mg

  1. Khoo Teck Puat Hospital

  2. Ng Teng Fong General Hospital

  3. Tan Tock Seng Hospital

Herceptin Powder For IV Infusion 440 mg

  1. National University Hospital

Herceptin Solution For SC Injection 600 mg/5 mL

  1. KK Women's and Children's Hospital

  2. National Cancer Centre

  3. Ng Teng Fong General Hospital

  4. National University Hospital

  5. Tan Tock Seng Hospital

List of monographs containing this active ingredient

Trastuzumab [Herceptin]

Trastuzumab [Herzuma®]

Trastuzumab [Ogivri™]

Pertuzumab + Trastuzumab [Phesgo]

Trastuzumab [Trazimera]

Pertuzumab + Trastuzumab #

Trastuzumab [Trazher]

Back to top